LGVN
Longeveron Inc.Longeveron Inc. reported revenue of $1.20M in its most recent fiscal year, down 49.9% on the year before. It kept -1893.6% of that as net income, and generated -$18.89M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -49.9% | 7.7% | 205 / 250 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -0.6% | 8.8% | 142 / 212 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | -26.6% | 7.5% | 174 / 192 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -10.0% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | -1.6% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 1.9% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -7.9% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 67.0% | 68.6% | 76 / 141 |
Operating margin Operating income as a share of revenue. | -1942.2% | -31.8% | — |
Net margin Net income as a share of revenue. | -1893.6% | -30.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | -1575.5% | -14.7% | — |
Return on equity Net income divided by shareholder equity. | -400.1% | -49.7% | 405 / 416 |
Return on assets Net income divided by total assets. | -221.3% | -37.5% | 449 / 474 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -1814.3% | -45.2% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.25x | — |
Current ratio Current assets over current liabilities. | 1.33x | 3.99x | 398 / 472 |
Quick ratio Current assets excluding inventory, over current liabilities. | 1.33x | 3.62x | 385 / 472 |
Interest coverage Operating income divided by interest expense. | Not reported | -11.95x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 17 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Agafonova Nataliya Chief Medical Officer | Withheld for tax | 2,913 | $2.59 | $7.5K |
| Oct 1, 2026 | Blass Devin CTO & SVP of CMC | Withheld for tax | 2,520 | $2.59 | $6.5K |
| Oct 1, 2026 | Lehr Paul T General Counsel, Secretary | Withheld for tax | 2,253 | $2.59 | $5.8K |
| Oct 1, 2026 | Willard Stephen H Chief Executive Officer | Withheld for tax | 1,987 | $2.59 | $5.1K |
| Oct 1, 2026 | Jhaveri Nirav S. Chief Financial Officer | Withheld for tax | 742 | $2.59 | $1.9K |
| Aug 19, 2026 | Desai Arjun JJ Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Ungaro Ursula Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Paletta George A. Jr. Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Soffer Rock Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Hajjar Roger Joseph Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Lehr Paul T General Counsel, Secretary | Grant or award | 286,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Agafonova Nataliya Chief Medical Officer | Grant or award | 286,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Hare Joshua Chief Scientific Officer | Grant or award | 286,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Cann Leah Rush Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Ascheim Deborah Director | Grant or award | 36,000 | $0.00 | $0.00 |
| Aug 19, 2026 | Blass Devin CTO & SVP of CMC | Grant or award | 286,000 | $0.00 | $0.00 |
| Aug 17, 2026 | Jhaveri Nirav S. Chief Financial Officer | Grant or award | 300,000 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.20M | $2.39M | $709.0K | $1.22M | $1.31M | $5.63M |
| Gross profit | $803.0K | $1.88M | $221.0K | $497.0K | $590.0K | $1.83M |
| Operating income | -$23.29M | -$16.52M | -$21.03M | -$18.04M | -$17.46M | -$3.78M |
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M | -$17.05M | -$3.72M |
| EPS (diluted) | -$1.29 | n/c | n/c | n/c | n/c | n/c |
| Operating cash flow | -$18.64M | -$13.87M | -$19.00M | -$13.97M | -$9.64M | -$2.36M |
| Capital expenditure | $245.0K | $655.0K | $301.0K | $569.0K | $330.0K | $131.0K |
| Free cash flow | -$18.89M | -$14.52M | -$19.30M | -$14.54M | -$9.97M | -$2.50M |
| Total assets | $10.26M | $25.56M | $12.08M | $27.41M | $42.77M | $9.24M |
| Shareholder equity | $5.67M | $21.89M | $6.74M | $20.50M | $37.45M | $1.96M |
| Total debt | — | — | — | — | — | $450.0K |
| Cash | $4.66M | $19.23M | $4.95M | $10.50M | $25.66M | $816.0K |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from Longeveron Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 17, 2026. View filings on EDGAR.